Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials.
Khouja M, Jiang L, Pal K, Stewart PJ, Regmi B, Schwarz M, Klapper W, Alig SK, Darzentas N, Kluin-Nelemans HC, Hermine O, Dreyling M, Gonzalez de Castro D, Hoster E, Pott C; European Mantle Cell Lymphoma Network. Khouja M, et al. Among authors: gonzalez de castro d. Leukemia. 2024 Dec;38(12):2675-2684. doi: 10.1038/s41375-024-02375-8. Epub 2024 Sep 16. Leukemia. 2024. PMID: 39284897 Free PMC article.
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin J, Marais R, Porta N, Gonzalez de Castro D, Parsons L, Messiou C, Stamp G, Thompson L, Edmonds K, Sarker S, Banerji J, Lorigan P, Evans TRJ, Corrie P, Marshall E, Middleton MR, Nathan P, Nicholson S, Ottensmeier C, Plummer R, Bliss J, Valpione S, Turajlic S. Larkin J, et al. Among authors: gonzalez de castro d. Cell Rep Med. 2024 Mar 19;5(3):101435. doi: 10.1016/j.xcrm.2024.101435. Epub 2024 Feb 27. Cell Rep Med. 2024. PMID: 38417447 Free PMC article. Clinical Trial.
EuroClonality-NGS Recommendations for Evaluation of B-Cell Clonality Analysis by Next-Generation Sequencing: A Structured Approach with the DEPART Algorithm.
van den Brand M, Möbs M, Otto F, Kroeze LI, Gonzalez de Castro D, Stamatopoulos K, Davi F, Bravetti C, Kolijn PM, Vlachonikola E, Stewart JP, Pott C, Hummel M, Darzentas N, Langerak AW, Fend F, Groenen PJTA. van den Brand M, et al. Among authors: gonzalez de castro d. J Mol Diagn. 2023 Oct;25(10):729-739. doi: 10.1016/j.jmoldx.2023.06.011. Epub 2023 Jul 17. J Mol Diagn. 2023. PMID: 37467928 Free article.
Redefining the high-grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report.
Rodríguez-Pinilla SM, Salgado RN, Chamizo C, Santonja C, Stewart P, Carvajal N, McCafferty N, Manso R, Morillo D, Piris MÁ, González de Castro D. Rodríguez-Pinilla SM, et al. Among authors: gonzalez de castro d. EJHaem. 2021 Nov 9;3(1):171-174. doi: 10.1002/jha2.310. eCollection 2022 Feb. EJHaem. 2021. PMID: 35846201 Free PMC article.
FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas.
Milton CI, Selfe J, Aladowicz E, Man SYK, Bernauer C, Missiaglia E, Walters ZS, Gatz SA, Kelsey A, Generali M, Box G, Valenti M, de Haven-Brandon A, Galiwango D, Hayes A, Clarke M, Izquierdo E, Gonzalez De Castro D, Raynaud FI, Kirkin V, Shipley JM. Milton CI, et al. Among authors: gonzalez de castro d. Mol Oncol. 2022 Mar;16(6):1272-1289. doi: 10.1002/1878-0261.13145. Epub 2021 Dec 18. Mol Oncol. 2022. PMID: 34850536 Free PMC article.
Indolent clinical behaviour of primary cutaneous diffuse large B-cell lymphoma, leg type, with double MYC and BCL6 gene rearrangement.
Rodríguez-Pinilla SM, Santonja C, Stewart P, Carvajal N, McCafferty N, Manso R, Meizoso T, Caro Gutiérrez MD, Piris MÁ, González de Castro D. Rodríguez-Pinilla SM, et al. Among authors: gonzalez de castro d. Br J Haematol. 2020 Nov;191(3):e83-e86. doi: 10.1111/bjh.17038. Epub 2020 Aug 11. Br J Haematol. 2020. PMID: 32780869 Free article. No abstract available.
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.
Pearson A, Proszek P, Pascual J, Fribbens C, Shamsher MK, Kingston B, O'Leary B, Herrera-Abreu MT, Cutts RJ, Garcia-Murillas I, Bye H, Walker BA, Gonzalez De Castro D, Yuan L, Jamal S, Hubank M, Lopez-Knowles E, Schuster EF, Dowsett M, Osin P, Nerurkar A, Parton M, Okines AFC, Johnston SRD, Ring A, Turner NC. Pearson A, et al. Among authors: gonzalez de castro d. Clin Cancer Res. 2020 Feb 1;26(3):608-622. doi: 10.1158/1078-0432.CCR-18-4044. Epub 2019 Oct 7. Clin Cancer Res. 2020. PMID: 31591187
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.
Brown SR, Hall A, Buckley HL, Flanagan L, Gonzalez de Castro D, Farnell K, Moss L, Gregory R, Newbold K, Du Y, Flux G, Wadsley J. Brown SR, et al. Among authors: gonzalez de castro d. BMC Cancer. 2019 Jun 14;19(1):582. doi: 10.1186/s12885-019-5541-4. BMC Cancer. 2019. PMID: 31200667 Free PMC article.
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Sclafani F, Wilson SH, Cunningham D, Gonzalez De Castro D, Kalaitzaki E, Begum R, Wotherspoon A, Capdevila J, Glimelius B, Roselló S, Thomas J, Tait D, Brown G, Oates J, Chau I. Sclafani F, et al. Among authors: gonzalez de castro d. Int J Cancer. 2020 Jan 1;146(1):94-102. doi: 10.1002/ijc.32507. Epub 2019 Jul 5. Int J Cancer. 2020. PMID: 31199501 Clinical Trial.
37 results